Yagiz A Aksoy, Bin Xu, Kartik Viswanathan, Mahsa S Ahadi, Abir Al Ghuzlan, Bayan Alzumaili, Mohamed-Amine Bani, Justine A Barletta, Nicole Chau, Angela Chou, Adele Clarkson, Roderick J Clifton-Bligh, Antonio De Leo, Snjezana Dogan, Ian Ganly, Ronald Ghossein, Matti L Gild, Anthony R Glover, Julien Hadoux, Livia Lamartina, Daniel J Lubin, Kelly Magliocca, Fedaa Najdawi, Arad Nigam, Alex Papachristos, Andrea Repaci, Bruce G Robinson, Amy Sheen, Qiuying Shi, Stan B Sidhu, Loretta Sioson, Erica Solaroli, Mark S Sywak, Giovanni Tallini, Venessa Tsang, John Turchini, Brian R Untch, Anthony J Gill, Talia L Fuchs
AIMS: Recently, there have been attempts to improve prognostication and therefore better guide treatment for patients with medullary thyroid carcinoma (MTC). In 2022, the International MTC Grading System (IMTCGS) was developed and validated using a multi-institutional cohort of 327 patients. The aim of the current study was to build upon the findings of the IMTCGS to develop and validate a prognostic nomogram to predict recurrence-free survival (RFS) in MTC. METHODS AND RESULTS: Data from 300 patients with MTC from five centres across the USA, Europe, and Australia were used to develop a prognostic nomogram that included the following variables: age, sex, AJCC stage, tumour size, mitotic count, necrosis, Ki67 index, lymphovascular invasion, microscopic extrathyroidal extension, and margin status...
January 22, 2024: Histopathology